SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SG-2501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SG-2501 is under development for the treatment of hematological tumors like multiple myeloma, chronic lymphocytic leukemia, primary systemic amyloidosis, Waldenstrom macroglobulinemia, b-cell Hodgkin lymphoma, non-Hodgkin lymphoma, relapsed multiple myeloma, refractory multiple myeloma and diffuse large b-cell lymphoma. The drug candidate is a bi-specific monoclonal antibody and acts by targeting cell surface antigen CD38/CD47. The drug candidate is administered through intravenous route.
Hangzhou Sumgen Biotech overview
Hangzhou Sumgen Biotech formerly Hangzhou Shangjian Biotechnology Co Ltd is a drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnostics. Shangjian Biotechnology is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of SG-2501’s drug-specific PTSR and LoA scores, buy the report here.